Search Results for “” – Page 10

ENYO Pharma Announces 16 Weeks Vonafexor (EYP001) Top-Line Interim Results from Two on-going Phase 2a Studies in Chronic Hepatitis B Patients

Lyon, France. July 30, 2021 – ENYO Pharma (ENYO), a private clinical stage biotechnology company developing innovative drug candidates, today announced positive proof of concept data from Study EYP001-203 of Vonafexor in combination with pegylated-Interferon (peg-IFN) in viremic patients with chronic hepatitis B (CHB).

Published on 30/07/2021

Fierce Biotech – Enyo Pharma’s NASH results show boost in kidney function, differentiating vonafexor from busy field

https://www.fiercebiotech.com/biotech/enyo-pharma-s-nash-results-show-boost-kidney-function-differentiating-vonafexor-from-busy

Published on 29/07/2021

ENYO Pharma Announces Positive Vonafexor (EYP001) Results for the LIVIFY Phase 2a Study in F2-F3 NASH Patients over 12 weeks

Lyon, France. July 28, 2021 – ENYO Pharma, a private clinical stage biotechnology company developing innovative drug candidates, today announced that Vonafexor met the primary and several secondary endpoints in the LIVIFY clinical study conducted in F2-F3 Non Alcoholic Steato-Hepatitis (NASH) patients.

Published on 28/07/2021